Exploring new ways to improve HIV vaccines using insights from COVID-19 vaccines
Official title: Synergizing neutralization and non-neutralization antibody targets at the HIV/SIV viral spike apex
Funded at New York University School of Medicine · NIH-10838922 · Data updated 2026-11-12
This study is exploring how what we learned from making COVID-19 vaccines can help us create a better vaccine for HIV by focusing on specific parts of the virus to boost our immune response, and it involves lab tests and models to see how well these new ideas work.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | August 9, 2024 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $228,825 |
| NIH project number | 1R21AI181677-01 |
| Project ID | NIH-10838922 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at high risk for HIV infection who are seeking preventive measures.
✕Less likely to help
Patients who are already living with HIV or those who are not at risk for HIV infection may not benefit from this research.
What this research studies
This research investigates how insights gained from the development of COVID-19 vaccines can be applied to create a more effective HIV vaccine. The approach focuses on enhancing immune responses by targeting specific antibody sites on the HIV virus. By studying the similarities between the viral structures of HIV and SARS-CoV-2, researchers aim to identify key B-cell epitopes that can improve vaccine efficacy. The study includes both laboratory experiments and preclinical models to test the effectiveness of these new vaccine strategies.
Why it matters
Potential benefit: If successful, this research could lead to the development of a highly effective HIV vaccine, significantly reducing the risk of HIV acquisition.
How similar studies have gone: Previous research has shown promising results in using similar approaches to enhance vaccine efficacy against other viral infections, indicating potential for success in this area.
Where this research is happening
-
New York University School of Medicine
New York, United States Active
Researchers
- Principal investigator: Cardozo, Timothy J — New York University School of Medicine
- Study coordinator: Cardozo, Timothy J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.